The research organization has collaborated with a startup to develop ways to enhance stem cell production
OpenAI has unveiled a new language model, dubbed GPT-4b micro, which is specifically designed to help scientists extend the human lifespan, as reported by MIT Technology Review. The leading artificial intelligence research entity has collaborated with a company called Retro Biosciences on a project aimed at improving stem cell production by re-engineering certain proteins.
Stem cells are crucial in regenerative medicine due to their ability to differentiate into various cell types, offering potential treatments for age-related diseases.
Founded in 2021, Retro Biosciences is a startup focused on lengthening the human lifespan through cellular reprogramming. In 2022, OpenAI CEO Sam Altman invested $180 million in the company.
GPT-4b micro looks for ways to modify Yamanaka factors, which are proteins capable of converting adult cells into stem cells. Preliminary tests have indicated that proteins redesigned by the model are over 50 times more effective at inducing stem cell production than their natural counterparts.
The model was trained on extensive biological data from numerous species, enabling it to predict protein structures and interactions more accurately than traditional methods.
In an article from Friday, MIT Technology Review quoted one of the model’s developers at OpenAI, John Hallman, as saying that “just across the board, the proteins seem better than what the scientists were able to produce by themselves.”
GPT-4b micro is currently in the research phase and not yet available for public use. OpenAI plans to publish the results for peer review at a later date.
Another developer on the project, Aaron Jaech, told MIT Technology Review that the project is meant to cement OpenAI’s position in scientific research. He added that it is still too early to tell “whether those capabilities will come out to the world as a separate model or whether they’ll be rolled into our mainline reasoning models.”
Back in 2018, Google developed the first iteration of its AlphaFold – an AI model specializing in figuring out complex 3D structure of proteins. AlphaFold is able to handle the task within mere minutes, “to a remarkable degree of accuracy,” Google DeepMind says on its website.
While working in a related field, GPT-4b micro uses different principles to help researchers to effectively re-engineer specific proteins.
In recent years, multiple research teams around the world have been experimenting with AI in a quest to develop novel treatments. A study published in the scientific journal Nature on Wednesday suggested that AI-designed proteins could neutralize deadly snake venom.
In 2022, researchers with the University of Washington School of Medicine and Harvard University announced that they had managed to train several image-generating AI models to devise new proteins that could prove useful in the development of vaccines and cancer treatments, among other uses.
“The proteins we find in nature are amazing molecules, but designed proteins can do so much more,” David Baker, a professor of biochemistry at UW Medicine and senior author on the study said at the time. He went on to receive the 2024 Nobel Prize in Chemistry for computational protein design.
